Activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway overcomes cisplatin resistance in ovarian carcinoma cells

International Journal of Gynecological Cancer

Volumn 22, Issue 6, 2012, Pages 922-929

  Nonaka, Michiko ^a   Itamochi, Hiroaki ^a   Kawaguchi, Wakae ^a   Kudoh, Akiko ^a   Sato, Seiya ^a   Uegaki, Kazunori ^a   Naniwa, Jun ^a   Sato, Shinya ^a   Shimada, Muneaki ^a   Oishi, Tetsuro ^a   Terakawa, Naoki ^a   Kigawa, Junzo ^a   Harada, Tasuku ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Cisplatin; MEK ERK; Molecular targeted therapy; Ovarian carcinoma; Resistance

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; CASPASE 9; CISPLATIN; MITOGEN ACTIVATED PROTEIN KINASE; PHORBOL 13 ACETATE 12 MYRISTATE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CARCINOMA CELL; CELL CYCLE S PHASE; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY TEST; DOWN REGULATION; DRUG ANTAGONISM; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME DEGRADATION; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL RATE; TUMOR XENOGRAFT; UPREGULATION;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEATH; CELL LINE, TUMOR; CHROMONES; CISPLATIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; FLAVONOIDS; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MORPHOLINES; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; S PHASE; TETRADECANOYLPHORBOL ACETATE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863616518     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31824f0b13     Document Type: Article

References (27)

1. Global Cancer Facts & Figures 2007. Available from: http://www.cancer.org/Research/CancerFactsFigures/GlobalCancerFactsFigures/ global-cancer-facts-figures-2007. Accessed January 8, 2012.
2. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clinl Oncol. 2002;20:1248-1259.
3. FIGO (International Federation of Gynecology and Obstetrics) annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2003;83(suppl 1):ixYxxii, 1-229.
4. Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009;27:1419-1425.
5. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005;4:307-320.
6. Altomare DA, Wang HQ, Skele KL, et al. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene. 2004;23:5853-5857.
7. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol. 2010;28: 1075-1083.
8. Montagut C, Settleman J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett. 2009;283:125-134.
9. Rinehart J, Adjei AA, Lorusso PM, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol. 2004;22:4456-4462.
10. Bellacosa A, de Feo D, Godwin AK, et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer. 1995;64:280-285.
11. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27-55.
12. Kawaguchi W, Itamochi H, Kigawa J, et al. Simultaneous inhibition of the mitogen-activated protein kinase kinase and phosphatidylinositol 3'-kinase pathways enhances sensitivity to paclitaxel in ovarian carcinoma. Cancer Sci. 2007;98:2002-2008.
13. Besson A, Davy A, Robbins SM, et al. Differential activation of ERKs to focal adhesions by PKC epsilon is required for PMA-induced adhesion and migration of human glioma cells. Oncogene. 2001;20:7398-7407.
14. McCubrey JA, Steelman LS, Abrams SL, et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul. 2006;46:249-279.
15. Ussar S, Voss T. MEK1 and MEK2, different regulators of the G1/S transition. J Biol Chem. 2004;279:43861-43869.
16. Persons DL, Yazlovitskaya EM, Cui W, et al. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin Cancer Res. 1999;5:1007-1014.
17. Wang X, Martindale JL, Holbrook NJ. Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem. 2000;275:39435-39443.
18. Lee S, Yoon S, Kim DH. A high nuclear basal level of ERK2 phosphorylation contributes to the resistance of cisplatin-resistant human ovarian cancer cells. Gynecol Oncol. 2007;104:338-344.
19. Hayakawa J, Ohmichi M, Kurachi H, et al. Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. The Journal of biological chemistry. 1999;274:31648-31654.
20. Sheridan C, Brumatti G, Elgendy M, et al. An ERK-dependent pathway to Noxa expression regulates apoptosis by platinum-based chemotherapeutic drugs. Oncogene. 2010;29:6428-6441.
21. Schonwasser DC, Marais RM, Marshall CJ, et al. Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes. Mol Cell Biol. 1998;18:790-798.
22. Strair RK, Schaar D, Goodell L, et al. Administration of a phorbol ester to patients with hematological malignancies: preliminary results from a phase I clinical trial of 12-O-tetradecanoylphorbol- 13-acetate. Clin Cancer Res. 2002;8:2512-2518.
23. Cui XX, Chang RL, Zheng X, et al. A sensitive bioassay for measuring blood levels of 12-O-tetradecanoylphorbol-13-acetate (TPA) in patients: preliminary pharmacokinetic studies. Oncol Res. 2002;13:169-174.
24. Schaar D, Goodell L, Aisner J, et al. A phase I clinical trial of 12-O-tetradecanoylphorbol-13-acetate for patients with relapsed/refractory malignancies. Cancer Chemother Pharmacol. 2006;57:789-795.
25. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22:7265-7279.
26. Ashwell S, Zabludoff S. DNA damage detection and repair pathways-recent advances with inhibitors of checkpoint kinases in cancer therapy. Clin Cancer Res. 2008;14:4032-4037.
27. Peng DJ, Wang J, Zhou JY, et al. Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells. Biochem Biophys Res Commun. 2010;394:600-605.